Serum potassium, calcium and magnesium in patients receiving ESHAP chemotherapy for relapsed lymphomas

Journal of the Royal College of Physicians of Edinburgh

Volumn 39, Issue 4, 2009, Pages 301-306

  Zekri, J ^a   Cheah, N L C ^a   Evans, L ^a   Hancock, B ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Cisplatin; ESHAP; Hypocalcaemia; Hypokalaemia; Hypomagnesaemia

Indexed keywords

BENDROFLUMETHIAZIDE; CALCIUM; CISPLATIN; CYTARABINE; DIURETIC AGENT; ETOPOSIDE; FUROSEMIDE; MAGNESIUM; METHYLPREDNISOLONE; POTASSIUM;

ARTICLE; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL PRACTICE; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; LYMPHOMA; MAGNESIUM BLOOD LEVEL; MAGNESIUM METABOLISM; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; POTASSIUM BALANCE; POTASSIUM BLOOD LEVEL;

EID: 74249085769     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2009.403     Document Type: Article

References (25)

1. Choi CW, Paek CW, Seo JH et al. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma. J Korean Med Sci 2002; 17:621-4.
2. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:2766-70.
3. Lajer H, Kristensen M, Hansen HH et al. Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol 2005; 55:231-6. doi:10.1007/s00280-004-0899-6
4. Elisaf M, Milionis H, Siamopoulos KC. Hypomagnesemic hypokalemia and hypocalcemia: clinical and laboratory characteristics. Miner Electrolyte Metab 1997; 23:105-12.
5. Hoffmann K, Marten A, Lindel K et al. Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759]. BMC Cancer 2006; 6:128. doi:10.1186/1471-2407-6-128
6. Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 1982; 9:75-83.
7. Cvitkovic E, Spaulding J, Bethune V et al. Improvement of cisdichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39:1357-61. doi:10.1002/1097-0142(197704)39:4〈1357:: AID-CNCR2820390402〉3.0.CO;2-C
8. Hayes D, Cvitkovic E, Golbey R et al. High dose cis-platinum diamine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39:1372. doi:10.1002/1097-0142(197704)39:4〈1372:: AIDCNCR2820390404〉 3.0.CO;2-J
9. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 1993; 27:1519-25.
10. Wolfgang GH, Dominick MA, Walsh KM et al. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol 1994; 22:73-9. doi:10.1006/faat.1994.1010
11. Dentino M, Luft FC, Yum MN et al. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41:1274-81. doi:10.1002/1097-0142(197804)41:4〈1274:: AID-CNCR2820410410〉3.0.CO;2-F
12. Stewart DJ, Mikhael NZ, Nanji AA et al. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. J Clin Oncol 1985; 3:1251-6.
13. Rodriguez M, Solanki DL, Whang R. Refractory potassium repletion due to cisplatin-induced magnesium depletion. Arch Intern Med 1989; 149:2592-4. doi:10.1001/archinte.149.11.2592
14. Whang R, Whang DD, Ryan MP. Refractory potassium repletion. A consequence of magnesium deficiency. Arch Intern Med 1992; 152:40-5. doi:10.1001/archinte.152.1.40
15. Mohammadianpanah M, Omidvari S, Mosalaei A et al. Cisplatin-induced hypokalemic paralysis. Clin Ther 2004; 26:1320-3. doi:10.1016/S0149- 2918(04)80177-2
16. Stewart AF, Keating T, Schwartz PE. Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstet Gynecol 1985; 153:660-5.
17. Gomez Campdera FJ, Gonzalez P, Carrillo A et al. Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure. Int J Pediatr Nephrol 1986; 7:151-2.
18. Ariceta G, Rodriguez-Soriano J, Vallo A et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 1997; 28:35-40. doi:10.1002/(SICI)1096-911X(199701)28:1〈35::AIDMPO7〉 3.0.CO;2-U
19. Ashraf M, Scotchel PL, Krall JM et al. Cis-platinum-induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol 1983; 16:309-18. doi:10.1016/0090-8258(83)90156-7
20. Bashir H, Crom D, Metzger M et al. Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. Pediatr Blood Cancer 2007; 49:867-9. doi:10.1002/pbc.20804
21. Buckley JE, Clark VL, Meyer TJ et al. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 1984; 144:2347-8. doi:10.1001/archinte.144.12.2347
22. Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care 2008; 35:215-37. doi:10.1016/j.pop.2008.01.007
23. Barton CH, Vaziri ND, Martin DC et al. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med 1987; 83:693-9. doi:10.1016/0002-9343(87)90900-4
24. Rolla G, Bucca C, Bugiani M et al. Hypomagnesemia in chronic obstructive lung disease: effect of therapy. Magnes Trace Elem 1990; 9:132-6.
25. Hartmann JT, Fels LM, Knop S et al. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000; 18:281-9. doi:10.1023/A:1006490226104